U.S. markets closed

Summit Therapeutics Inc. (SMMT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.2800+0.0700 (+1.66%)
At close: 4:00PM EST
Get access to 40+ years of historical data with Yahoo Finance Premium.Learn more
Currency in USD

Valuation Measures

Premium required to access annual data
Annual
Quarterly
Premium required to access monthly data
Monthly
Subscribe to Premium to download historical data
 
As of Date: 11/26/2020
Current
9/30/20206/30/20203/31/202010/31/20199/30/2019
Market Cap (intraday) 5
352.07M231.28M39.94M7.80M5.43M5.89M
Enterprise Value 3
331.35M168.68M-14.20M-8.77M-18.92M-29.53M
Trailing P/E
N/AN/AN/AN/AN/A9.45
Forward P/E 1
N/AN/AN/AN/AN/AN/A
PEG Ratio (5 yr expected) 1
N/AN/AN/AN/AN/AN/A
Price/Sales (ttm)
202.60165.55142.93114.05108.303.73
Price/Book (mrq)
9.403.4314.8022.996.465.75
Enterprise Value/Revenue 3
109.01931.96-83.53-28.01-118.26-199.51
Enterprise Value/EBITDA 6
-11.09-9.720.921.272.014.77

Trading Information

Stock Price History

Beta (5Y Monthly) 0.59
52-Week Change 3185.33%
S&P500 52-Week Change 315.56%
52 Week High 35.5000
52 Week Low 31.1800
50-Day Moving Average 33.7068
200-Day Moving Average 33.5424

Share Statistics

Avg Vol (3 month) 3104.3k
Avg Vol (10 day) 3262.06k
Shares Outstanding 582.26M
Float 19.3M
% Held by Insiders 173.57%
% Held by Institutions 19.93%
Shares Short (Nov 12, 2020) 457.97k
Short Ratio (Nov 12, 2020) 40.44
Short % of Float (Nov 12, 2020) 40.15%
Short % of Shares Outstanding (Nov 12, 2020) 40.07%
Shares Short (prior month Oct 14, 2020) 481.94k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2019
Most Recent Quarter (mrq)Sep 29, 2020

Profitability

Profit Margin -227.63%
Operating Margin (ttm)-247.56%

Management Effectiveness

Return on Assets (ttm)N/A
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)22.09M
Revenue Per Share (ttm)0.12
Quarterly Revenue Growth (yoy)22.30%
Gross Profit (ttm)17.18M
EBITDA -54.19M
Net Income Avi to Common (ttm)-50.29M
Diluted EPS (ttm)-0.2640
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)21.27M
Total Cash Per Share (mrq)0.26
Total Debt (mrq)548k
Total Debt/Equity (mrq)1.49
Current Ratio (mrq)2.85
Book Value Per Share (mrq)0.55

Cash Flow Statement

Operating Cash Flow (ttm)-48.38M
Levered Free Cash Flow (ttm)N/A